News

(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) Wednesday said its Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary goal of hemoglobin response.

42.3% of patients treated with mitapivat achieved a hemoglobin response, compared to 1.6% of patients who were given placebo.

Hemoglobin response was defined as an increase of more than or equal to 1 g/dL in average hemoglobin concentrations from Week 12 through Week 24 compared with baseline.

Agios is also advancing Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia and expects to announce topline data in mid-2024.

The company plans to file for regulatory approval of mitapivat as a treatment for thalassemia by the end of 2024.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.